DUPIXENT is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma.

DUPIXENT is a GINA-recognized treatment option for children with asthma aged 6-11 years and has a demonstrated safety profile.1,6,9